Search Results
Your search for them matches 6128 pages
Showing 1451 - 1500Newer Cancer Therapies Offer Hope but Also May Confer Cardiac Risk
Since many different chemotherapeutic agents have been linked with cardiac adverse events, there is a growing need for strategies for the assessment and mitigation of treatment-induced cardiotoxicity. Moreover, the rapid rise of immunotherapies has added a new dimension to this clinical setting....
Mammen Chandy, MD, FRACP, FRACPA: A Pioneer in India’s Bone Marrow Transplantation Services
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with bone marrow transplant expert Mammen Chandy, MD, FRACP, FRACPA, Director of Tata Medical Center, in Kolkata, India. Dr. Chandy was instrumental in establishing the first sustained bone marrow...
Patients With Hormone Receptor–Positive Breast Cancer and Emergent ESR1 Mutations May Benefit From Early Switch to Fulvestrant/Palbociclib
Among patients with hormone receptor–positive breast cancer treated with an aromatase inhibitor plus palbociclib, those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to fulvestrant plus...
Jordan’s Queen Rania Presents King Hussein Awards for Cancer Research
Her Majesty Queen Rania Al Abdullah of Jordan honored recipients of the 2021 King Hussein Award for Cancer Research during ceremony held on November 14 by the King Hussein Cancer Foundation (KHCF). The event was conducted under the patronage of Their Majesties King Abdullah II and Queen Rania Al...
Radiation Therapy for HPV-Related Oropharyngeal Squamous Cell Carcinoma: Prospects and Controversies
In the treatment of patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma, neither cancer outcomes nor measurable quality of life have yet been shown to differ between surgery- and radiotherapy-based approaches, according to Sue S. Yom, MD, PhD, FASTRO, Professor of ...
Applying Research Data to Clinical Practice in Managing Head and Neck Cancer
The 2021 Winship Cancer Institute of Emory University Symposium: Updates in the Management of Head and Neck Cancer explored current paradigms for the multidisciplinary treatment of head and neck cancer.1 Moderated by Nabil F. Saba, MD, FACP, the Lynne and Howard Halpern Chair in Head and Neck...
To Elect or Forgo Radiation Therapy: An Informed Decision for Patients With Breast Cancer
Advances intreating breast cancer “increasingly create opportunities to consider where radiation therapy might safely be omitted,” Reshma Jagsi, MD, DPhil, told participants at the 2021 Lynn Sage Breast Cancer Symposium.1 “But, I would encourage us,” she continued, “not to assume that women who...
How Medical Oncology Came to Be
For many, the way things are when you learn about them is assumed to be the way things have always been. For example, antibiotics are wonderful—but if you were practicing medicine when penicillin was discovered, it would have seemed like a miracle. For most of us, there have always been chemical...
Establishing a Health Equity Report Card to Eradicate Disparities in Cancer Care
Although enormous progress over the past 50 years in every aspect of cancer care, including prevention, screening, chemotherapy, targeted therapy, surgery, radiation therapy, and supportive care, has resulted in increases in lives saved—from 3 million in 1971 to 16.9 million in 2019—the burden of...
Single-Cell Spatial Analysis May Help to Predict Response to Neoadjuvant Atezolizumab in Patients With Triple-Negative Breast Cancer
A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab to chemotherapy as...
Researchers Identify Significant Differences in Tumor Characteristics Between Younger and Older Patients With Cancer
Investigators at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older patients with cancer across several cancer types. Their research, published by Shah et al in Cell Reports, suggests that cancer treatment could...
COVID-19 Vaccination: Patients With Multiple Myeloma May Lack T-Cell Response
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccination may also fail to mount a T-cell response, researchers from the Icahn School of Medicine at Mount Sinai have reported. This scenario seemed to be most common among patients actively treated with anti-CD38 and...
To Elect or Forgo Radiation Therapy: An Informed Decision for Patients With Breast Cancer
Advances in treating breast cancer “increasingly create opportunities to consider where radiation therapy might safely be omitted,” Reshma Jagsi, MD, DPhil, told participants at the 2021 Lynn Sage Breast Cancer Symposium.1 “But, I would encourage us,” she continued, “not to assume that women who...
Aditya Bardia, MD, MPH, Comments on Findings From monarchE
The invited discussant of monarchE,1 Aditya Bardia, MD, MPH, Director, Breast Cancer Research, and Associate Professor of Medicine, Harvard Medical School, commented: “Based on a hazard ratio of 0.69 for invasive disease–free survival, the results are statistically significant and clinically...
Phase II Breast Cancer Trial: Large Declines in Ki67 Index Seen With Oral Selective Estrogen Receptor Degrader
In the phase II coopERA Breast Cancer trial, which evaluated two endocrine neoadjuvant therapies in estrogen receptor–positive, HER2-negative early breast cancer, the oral selective estrogen receptor degrader giredestrant led to a greater reduction in Ki67 level—a measure of cancer cell...
Research Assesses Molecular Hallmarks of Moles and Melanomas
Moles and melanomas both originate from the same type of cell—melanocytes. A study published by McNeal et al in eLife Magazine aimed to explain how common moles and melanomas form and why moles can subsequently change into melanoma. Melanocytes are cells that give color to the skin to protect it...
Addressing the Global Challenges of Cancer Prevention and Treatment
Nearly 20 million people around the world were diagnosed with cancer in 2020, with 10 million losing their lives to this devastating disease. We highlight here the salient points from our article published in CA: A Cancer Journal for Clinicians,1 which describes the major themes and...
American Cancer Society and Flatiron Health Announce Recipients of Real-World Data Impact Award
The American Cancer Society (ACS) and Flatiron Health recently presented the 2021 Real-World Data Impact Awards, which will support research into health disparities among patients with advanced pancreatic and breast cancers. This year marks the third year of the joint grant-making program, under...
Tools for High-Quality, Accessible Care
Tools that make it easier for patients to access care and for their physicians to monitor their health status have also emerged with the advent of digital resources. In the closing panel of the NCCN Policy Summit, participants described tools developed by their own organizations to improve quality...
The Promise and the Challenge: Experts and Innovators Explore the Impact of New Technologies in Cancer Care
Artificial intelligence, digital therapeutics, telehealth, biometric monitoring: the terms alone are enough to suggest that cancer care is entering a new age, one characterized by tools and practices based on technologic innovation. To explore the impact of these new tools, the National...
The Role of Spirituality in Palliative Care
National surveys consistently show that spirituality and religion are important components in the lives of most Americans, with more than 90% of adults expressing a belief in God and more than 70% identifying religion as one of the most important influences in their lives.1 Studies also show that...
Five Percent Overall Medicare Reimbursement Cut Estimated for Medical Oncology in 2022
On November 2, 2021, the Centers for Medicare & Medicaid Services (CMS) released the 2022 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) final rule. Although ASCO will analyze the rule in greater detail in the coming days, initial highlights from the rule are outlined...
Achieving Equity in Cancer Care for Adolescents and Young Adults With Cancer
Although cancer in adolescents and young adults (AYAs), defined by the National Cancer Institute as those between the ages of 15 and 39, is relatively rare—in 2020 nearly 90,000 AYAs were diagnosed with cancer and about 9,300 died of the disease1—and 5-year relative survival rates are high, between ...
Expert Point of View: Paul Wheatley-Price, MRCP
During an International Association for the Study of Lung Cancer (IASLC) press briefing, Paul Wheatley-Price, MRCP, commented as the patient advocate on the panel. Dr. Wheatley-Price is Associate Professor of Medicine at the University of Ottawa, lung cancer disease site lead at Ottawa Hospital...
UKLS Trial Meta-analysis Confirms Mortality Reduction With Low-Dose CT Screening for Lung Cancer
Low-dose lung cancer screening by computed tomography (CT) is associated with a 16% relative reduction in lung cancer mortality over no lung cancer screening of high-risk individuals, based on a meta-analysis conducted by investigators with the United Kingdom Lung Cancer Screening (UKLS) trial.1...
Novel Therapies Under Study in Acute Myeloid Leukemia
Newly identified genetic abnormalities in acute myeloid leukemia (AML), as well as therapies that can target some of those abnormalities, are now available as the landscape for treatment continues to evolve. During the 2021 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic...
Friends of Cancer Research Releases White Paper on Optimizing Dosing in Oncology Drug Development
During its virtual Annual Meeting 2021 held on November 9 and 10, Friends of Cancer Research (Friends) urged all stakeholders in the cancer community to work together to optimize dosing in oncology drug development to maximize benefit for patients and reduce treatment toxicity, and to abandon the...
Can SBRT to Selected Sites of Limited Progression or Oligoprogression Extend Progression-Free Survival in Advanced Lung Cancer but Not Breast Cancer?
Stereotactic body radiation therapy (SBRT) lengthens progression-free survival for patients with advanced lung cancer who have oligoprogression (ie, tumors that have not been fully responsive to systemic chemotherapy or immunotherapy), according to an interim analysis of the CURB oligoprogression...
From Cancer Survivor to Citizen Astronaut
When I was diagnosed with osteosarcoma of my left femur nearly 20 years ago, I remember telling my parents that I didn’t want to die. The diagnosis was terrifying because all the people I knew who had cancer had passed away, and I thought this cancer would kill me, too. That evening, my dad went...
Novel Therapies Under Study in Acute Myeloid Leukemia
Newly identified genetic abnormalities in AML have led to novel therapies that can target some of them, as the landscape for treatment continues to evolve. During the 2021 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies, Alice S. Mims MD, presented updates in...
For Liver Metastases, Transarterial Radioembolization With Yttrium-90 Plus Chemotherapy May Delay Disease Progression
In the international phase III EPOCH trial, patients with colorectal liver metastases who experienced disease progression on first-line therapy derived significant benefit from treatment with transarterial yttrium Y-90 radioembolization in combination with systemic chemotherapy, according to Mary...
Study Explores Method to Selectively Grow Tumor-Targeting T Cells for Cancer Therapy
A preclinical study published by Arnaud et al in Nature Biotechnology has demonstrated the utility and efficacy of a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens and destroy the tumors that express them. Developed by a team of...
ASCO Quality Improvement Programs Helped to Enhance the Delivery of Cancer Care in Medically Underserved Communities, Article Reports
Oncology practices that participated in a quality improvement project that included ASCO’s Quality Oncology Practice Initiative (QOPI®) and ASCO Quality Training Program (QTP) were able to make improvements in the care provided to underserved populations in their communities, according to a recent...
Living in Survival Mode
About 10 years ago, on a flight to Detroit, while returning from the San Antonio Breast Cancer Symposium, I had a conversation with Lori Pierce, MD, FASTRO, FASCO, radiation oncologist at the University of Michigan, who went on to become ASCO President for the 2020–2021 term. I recall inviting her...
David Morse Livingston, MD, Scientist and Esteemed Mentor, Dies at 80
David Morse Livingston, MD, formerly the Charles A. Dana Chair in Human Cancer Genetics at Dana-Farber and the Emil Frei III Distinguished Professor of Medicine at Harvard Medical School, died unexpectedly on October 17, 2021. He was Deputy Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) ...
Lung Cancer Research Foundation Names 2021 Recipients of Grant on Disparities in Lung Cancer
The Lung Cancer Research Foundation (LCRF) has announced the recipients of the 2021 LCRF Research Grant on Disparities in Lung Cancer, awarding $300,000 in research grants for projects focused on disparities in lung cancer. This funding mechanism will provide $150,000 over a period of 2 years...
Expert Point of View: Monica Arnedos, MD, PhD
The invited discussant of BrighTNess,1 Monica Arnedos, MD, PhD, Head of the Breast Cancer Research Program at the Institut Bergonié in Bordeaux, France, said the findings add to growing support for using carboplatin in triple-negative breast cancer, but their clinical application could be...
The Worst Part of Having Cancer Was the Guilt
When I was diagnosed with small cell lung cancer in 1992, at age 38, I remember thinking, “I wish I had breast cancer.” Breast cancer elicits such sympathy from people. A diagnosis of small cell lung cancer mainly gets you stern looks of disapproval and disappointment. There is so much stigma...
Cancer Researcher and Drug Developer, Joseph R. Bertino, MD, Dies at 91
Over the arc of his notable career, Joseph R. Bertino, MD, garnered many honors for his scientific contributions leading to curative treatments for leukemia and lymphoma, such as ASCO’s David A. Karnofsky Award. Yet his legacy was perhaps most prominently punctuated by the multitude of patients...
AML Pioneer and ‘Gentle Soul,’ Elihu H. Estey, MD, Dies at 75
“A lot of times, younger bright physicians are afraid to say what they really think, out of fear of challenging the dogma. One of the things I do when mentoring is to ask why we are doing a particular therapy or intervention. I tell my mentees not to let the data interfere with your knowledge,”...
Early Experiences in the United States Helped Shape an International Oncology Career for Aleix Prat, MD, PhD
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Aleix Prat, MD, PhD, Head of the Medical Oncology Department, Hospital Clinic of Barcelona. Dr. Prat, a breast cancer researcher, is currently working to identify strategies to tailor treatment for...
Study Examines Breakthrough COVID-19 Infection in Vaccinated Patients With Hematologic Cancers
People with blood cancers are at a higher risk than healthy individuals for severe infection with COVID-19; furthermore, research suggests that they do not always achieve optimal protection from vaccination. A new study published by Pagano et al in the journal Blood—the first to report on...
Fear of Side Effects and Lack of Awareness: Barriers to Greater Use of Risk-Reducing Medications for Breast Cancer
A “big problem, maybe the major one,” with risk-reducing medications for breast cancer is low uptake among women at high risk of breast cancer,” Seema A. Khan, MD, told participants at the 2021 Annual Lynn Sage Breast Cancer Symposium.1 Dr. Khan is Professor of Surgery and the Bluhm Family...
Risk-Reducing Medications for Breast Cancer Are Becoming Safer and More Tolerable
Risk-reducing medications for breast cancer may be effective for many women, and recently reported and ongoing trials have led to improvements in their tolerability and safety, Seema A. Khan, MD, reported at the 2021 Annual Lynn Sage Breast Cancer Symposium (virtual).1 Dr. Khan is Professor of...
Patients With Multiple Myeloma May Lack T-Cell Responses to COVID-19 Vaccination
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccine may also fail to mount a T-cell response, according to research from the Icahn School of Medicine at Mount Sinai. Concerningly, this scenario was most common among patients actively treated with anti-CD38 and...
FOCUS4-C Trial: Hint of Activity Reported With Adavosertib in Metastatic Colorectal Cancer
The novel WEE1 inhibitor adavosertib, given after induction chemotherapy, yielded a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with metastatic colorectal cancer and TP53/RAS mutations, according to the randomized phase II FOCUS4-C trial....
Annual Report to the Nation, Part 2: Focus on Patient Economic Burden Associated With Cancer Care
Part 2 of the latest Annual Report to the Nation on the Status of Cancer—provided by the American Cancer Society, National Cancer Institute, Centers for Disease Control and Prevention, and North American Association of Central Cancer Registries—has found that patients with cancer in the United...
Expert Point of View: Federica Di Nicolantonio, MD, PhD
“KRAS G12C inhibitors as monotherapy yield a relatively low overall response rate, but when you combine them with an EGFR [epidermal growth factor receptor] inhibitor, the response rate is nearly double,” said Federica Di Nicolantonio, MD, PhD, Professor of Oncology at the University of Turin in...
Is Precision Oncology an Unsustainable Promise?
Despite the promise of precision oncology, the cost-effectiveness of targeted treatments remains open to debate. According to Aakash Desai, MD, MPH, there is an urgent need for drug-pricing reform, given the average expenditure of Medicare Part D. An analysis of the Medicare database presented...
Having Stage IV Lung Cancer Has Refocused My Life
The first indication I had stage IV lung cancer was a persistent cough during the beginning of the cold-and-flu season in the fall of 2013. I was 35 years old, never smoked, and in otherwise excellent health, so I ignored the cough for several months until I noticed my breathing had also become...
